Obesity-drug maker Metsera posts largest gain as IPOs defy market swoon
Obesity-drug maker Metsera Inc.'s stock jumped 47% on Friday as the biggest gainer among three initial public offerings bucking a swoon in the equity market to rise in their stock-market debuts Friday ...
Live Science6h
FDA approves 1st new class of opioid-free painkillers in over 20 years
The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.
aha.org6h
FDA approves first-in-class non-opioid painkiller
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class ...
FDA approves first non-opioid pain medicine in more than 20 years
The Food and Drug Administration announced the approval of a new non-opioid pain medication this week, marking the first time ...
FDA Approves First New Non-Opiod Painkiller in Decades
Journavx is designed to eliminate the risks of addiction and overdose associated with medications like Vicodin and OxyContin.
FDA approves first new type of pain medication in 25 years
A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...
New Atlas23h
FDA approves new class of painkiller – the first in more than 20 years
The US Food and Drug Administration has approved the use of a novel painkiller as an effective treatment for short-term ...